Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.

Conway A, McCarthy AL, Lawrence P, Clark RA.

BMC Cancer. 2015 May 7;15:366. doi: 10.1186/s12885-015-1407-6. Review.

2.

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Cheuk DK, Sieswerda E, van Dalen EC, Postma A, Kremer LC.

Cochrane Database Syst Rev. 2016 Aug 23;(8):CD008011. doi: 10.1002/14651858.CD008011.pub3. Review.

PMID:
27552363
3.

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Sieswerda E, van Dalen EC, Postma A, Cheuk DK, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2011 Sep 7;(9):CD008011. doi: 10.1002/14651858.CD008011.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD008011.

PMID:
21901716
4.

Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.

Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.

Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. Review.

6.

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A.

BMC Cancer. 2010 Jun 29;10:337. doi: 10.1186/1471-2407-10-337. Review.

7.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen EC, Michiels EM, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2010 May 12;(5):CD005006. doi: 10.1002/14651858.CD005006.pub4. Review.

PMID:
20464735
8.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen EC, Michiels EM, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006. doi: 10.1002/14651858.CD005006.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005006.

PMID:
20238335
9.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen EC, Michiels EM, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005006. Review. Update in: Cochrane Database Syst Rev. 2010;(3):CD005006.

PMID:
17054231
10.

Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.

Wu V.

J Pediatr Oncol Nurs. 2015 May-Jun;32(3):178-84. doi: 10.1177/1043454214554008. Epub 2014 Nov 3. Review.

PMID:
25366577
11.

Cardiac complications in childhood cancer survivors treated with anthracyclines.

Franco VI, Lipshultz SE.

Cardiol Young. 2015 Aug;25 Suppl 2:107-16. doi: 10.1017/S1047951115000906. Review.

PMID:
26377717
12.

Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.

Olivieri J, Perna GP, Bocci C, Montevecchi C, Olivieri A, Leoni P, Gini G.

Oncologist. 2017 Apr;22(4):422-431. doi: 10.1634/theoncologist.2016-0289. Epub 2017 Mar 8.

13.

Chemotherapy-induced cardiotoxicity in children.

Bansal N, Amdani S, Lipshultz ER, Lipshultz SE.

Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):817-832. doi: 10.1080/17425255.2017.1351547. Epub 2017 Jul 13. Review.

PMID:
28679288
14.

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.

van Dalen EC, Raphaël MF, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006647. doi: 10.1002/14651858.CD006647.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD006647.

PMID:
19160293
15.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

Salvatorelli E, Menna P, Minotti G.

Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4. No abstract available.

16.

Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.

Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G.

Am J Cardiol. 2013 Dec 15;112(12):1980-4. doi: 10.1016/j.amjcard.2013.08.026. Epub 2013 Sep 25. Review.

PMID:
24075281
17.

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.

van Dalen EC, Raphaël MF, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006647. doi: 10.1002/14651858.CD006647.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;9:CD006647.

PMID:
21249679
18.

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status.

Horacek JM, Vasatova M, Pudil R, Tichy M, Zak P, Jakl M, Jebavy L, Maly J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Dec;158(4):511-7. doi: 10.5507/bp.2014.004. Epub 2014 Jan 23. Review.

19.

Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.

Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R.

Paediatr Drugs. 2005;7(2):67-76. Review.

PMID:
15871628
20.

Cardioprotective interventions for cancer patients receiving anthracyclines.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003917. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD003917.

PMID:
15674919

Supplemental Content

Support Center